IDRA News Alert Idera Pharmaceuticals (IDRA) 4.06 12/04/2014

New Post Public Reply Private Reply Replies (0) Message Board

Dec 4, 2014 at 6:30 PM

Idera Pharmaceuticals (IDRA) 4.06 $IDRA

Hawaiian Electric and Taser are big market movers
AP - 1 hr 54 mins ago
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:
TSLA: 228.28 (-1.02), HE: 32.22 (+4.03), PLUG: 3.70 (+0.20), CLV: 7.55 (-0.60), CLF: 8.03 (-0.57), BKS: 21.03 (-1.21), ARO: 2.48 (-0.71), RAD: 5.58 (+0.12), CARB: 14.21 (-0.23), SQNM: 3.67 (-0.10), ENB.TO: 60.04 (+5.61), RIG: 18.68 (-0.89), IDRA: 4.06 (-0.01), ANF: 27.90 (-0.91), ENB: 52.80 (+4.92), TASR: 24.15 (+1.29), AVGO: 103.07 (+7.94), PBYI: 195.55 (-2.12)

Traders Get Bullish on Shares of Idera Pharmaceuticals, Shares Up 7.0% (IDRA)
Comtex SmarTrend(R) - Wed Dec 03, 10:36AM CST
Idera Pharmaceuticals (NASDAQ:IDRA) is one of today's best performing low-priced stocks, up 7.0% to $3.83 on 3.7x average daily volume. Idera Pharmaceuticals has traded 2.7 million shares thus far today, vs. average volume of 727,000 shares per day. The stock has outperformed the Dow (7.0% to the Dow's 0.1%) and outperformed the S&P 500 (7.0% to the S&P's 0.2%) during today's trading.
IDRA: 4.06 (-0.01)

Idera up on preclinical data
Seeking Alpha - at Seeking Alpha - Wed Dec 03, 9:47AM CST

IDRA: 4.06 (-0.01)

Idera Pharmaceuticals Announces Cancer Immunotherapy Regimen With Intratumoral IMO-2055 Demonstrated Potent and Systemic Anti-Tumor Activity in Preclinical Models
GlobeNewswire - Tue Dec 02, 3:30PM CST
Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing nucleic acid therapeutics for patients with cancer and rare diseases, today announced new preclinical data that showed cancer immunotherapy with intratumoral injections of IMO-2055 and ipilimumab demonstrated potent and systemic anti-tumor activity in multiple preclinical cancer models. IMO-2055 is a synthetic oligonucleotide-based agonist of Toll-like receptor (TLR) 9 discovered and developed by Idera. Ipilimumab is a checkpoint inhibitor targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). The data were presented at the American Association for Cancer Research (AACR) Tumor Immunology and Immunotherapy Meeting in Orlando, Fla., earlier today.
IDRA: 4.06 (-0.01)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Dec 02, 11:47AM CST

CY: 12.48 (-0.03), QDEL: 24.01 (+0.22), WLT: 1.78 (-0.08), VNCE: 29.73 (-0.25), ISNS: 3.06 (+0.07), VII: 1.56 (-0.07), NTLS: 4.56 (+0.01), MFRM: 62.07 (-1.47), GSAT: 2.71 (-0.03), MOLG: 2.85 (-1.05), EVOK: 5.92 (-0.13), IDRA: 4.06 (-0.01), SCVL: 23.77 (+0.53), VGGL: 3.68 (-0.34), MIXT: 7.45 (-0.05), ENVI: 1.25 (+0.01), REI: 9.34 (+0.42), TRX: 0.88 (-0.01), DGLY: 21.00 (+3.08), CODE: 29.01 (+0.15)

Idera Announces Appointment of Robert A. Doody Jr. as Vice President of Investor Relations and Corporate Communications
GlobeNewswire - Tue Dec 02, 9:50AM CST
Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing nucleic acid therapeutics for cancers and rare diseases, announced that it has appointed Robert A. Doody Jr. as Vice President, Investor Relations and Corporate Communications.
IDRA: 4.06 (-0.01)

Idera Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference
GlobeNewswire - Tue Dec 02, 7:30AM CST
Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing novel nucleic acid therapeutics for cancer and rare diseases, today announced that Company management will present at the 26 Annual Piper Jaffray Healthcare Conference on Wednesday, December 3, 2014 at 3:30 p.m. EST in New York.
IDRA: 4.06 (-0.01)

Idera Pharmaceuticals Names Vincent J. Milano Chief Executive Officer
GlobeNewswire - Mon Dec 01, 5:06PM CST
-- Appointment brings commercial, operational and financial expertise
IDRA: 4.06 (-0.01), VNDA: 12.27 (-0.38)

New Chief at Idera
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 3:54PM CST

IDRA: 4.06 (-0.01)

Idera Pharmaceuticals (IDRA) Is Today's Strong On High Volume Stock
at The Street - Fri Nov 28, 9:03AM CST
Trade-Ideas LLC identified Idera Pharmaceuticals (IDRA) as a strong on high relative volume candidate
IDRA: 4.06 (-0.01)

Idera Pharmaceuticals: A Star In The Making
Samreen Agha - at Seeking Alpha - Wed Nov 26, 11:46AM CST

IDRA: 4.06 (-0.01)

Hot Stock: Idera Pharmaceuticals, Shares Gain 8.2% (IDRA)
Comtex SmarTrend(R) - Wed Nov 26, 10:05AM CST
Idera Pharmaceuticals (NASDAQ:IDRA) is one of today's best performing low-priced stocks, up 8.2% to $3.03 on 2.5x average daily volume. Idera Pharmaceuticals has traded 1.7 million shares thus far today, vs. average volume of 665,000 shares per day. The stock has outperformed the Dow (8.2% to the Dow's -0.1%) and outperformed the S&P 500 (8.2% to the S&P's 0.1%) during today's trading.
IDRA: 4.06 (-0.01)

Are Central Banks Panicking?
Leo Kolivakis - Seeking Alpha - Fri Nov 21, 12:50PM CST
Koh Gui Qing and Jason Subler of Reuters report, China surprises with interest rate cut to spur growth : China cut interest rates unexpectedly on Friday, stepping up efforts to support the world's second-biggest economy as it heads towards its...
PGNX: 7.25 (+0.15), BCRX: 9.92 (-0.66), AVNR: 16.96 (+0.04), ACAD: 30.46 (+0.05), IDRA: 4.06 (-0.01), QQQ: 105.37 (-0.05), SGEN: 36.50 (-0.91), XBI: 178.11 (-1.37), TGTX: 13.84 (-0.58), IBB: 306.20 (-2.05), THLD: 3.00 (+0.05), IWM: 116.81 (-0.56), TWTR: 38.79 (-0.27), XOMA: 4.46 (-0.30)

Idera Pharmaceuticals to Present at the Stifel 2014 Healthcare Conference
GlobeNewswire - Thu Nov 13, 7:30AM CST
Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing novel nucleic acid therapeutics for rare diseases, today announced that Company management will present at the Stifel 2014 Healthcare Conference on Wednesday, November 19, 2014 at 4:10 p.m. EST in New York.
IDRA: 4.06 (-0.01)

Idera Pharmaceuticals' (IDRA) CEO Sudhir Agrawal on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 11, 10:52PM CST

IDRA: 4.06 (-0.01)

Amgen's brodalumab beats Stelara in Phase 3 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 3:52PM CST

CANF: 4.04 (-0.23), JNJ: 107.56 (-0.16), IDRA: 4.06 (-0.01), DERM: 17.22 (+0.13), MRK: 60.92 (+0.34), PFE: 31.67 (-0.08), AZN: 73.94 (+0.12), AMGN: 166.55 (-1.52), GSK: 45.89 (-0.82), HSP: 59.26 (-0.48), NVS: 95.77 (+0.11), CELG: 113.63 (-0.60)

Idera ups revenues 329% in Q3
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 7:00AM CST

IDRA: 4.06 (-0.01)

Idera Pharmaceuticals EPS in-line
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 6:13AM CST

IDRA: 4.06 (-0.01)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Leapora's Taskeen: Redefining Task Accountability

AI's Impact on Workplace Task Management In today’s whirlwind of AI-generated output, transparency is not just a luxury; it’s a necessity. AI systems churn out work that can appear polished but often lacks substance. This doesn't just create headaches; it triggers a ticking bomb in the regulatory department. According to a 2025 survey from Stanford and BetterUp Labs,...

First-Time Homeowners: Unseen Pitfalls of Insurance

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Cracking the Code of America's Delivery Addiction

America's New Obsession: Convenience at a Cost Diving into the relentless hustle, Americans are shelling out big bucks to dodge life's mundane chores. A fresh survey dished out by FinanceBuzz, hitching a ride with Bank of America, gives us a peek into how hooked everyone is on convenience services like food and grocery deliveries. It’s clear people are ready to fork...

AI-Driven Lumi Transforms Car Dealership Interactions

Lumi: Changing the Car Buying Game Picture this: You're browsing for a new car, head filled with specifics like towing capacity, price points, and trim options. Usually, such queries would send you bouncing around the web, but Lectrium's Lumi promises to keep the questioning—and decision-making—right on the dealership's page. In a move set to shake up the game,...

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Dr. Desi Bartlett Teams Up with Glo for Perimenopause Focus

Glo Taps Top Wellness Expert for Women's Health Initiative In an industry brimming with wellness voices, it's rare to find one that marries scholarly acumen with authentic, personal teaching. Yet, this is precisely what Dr. Desi Bartlett brings to the table as she partners with Glo to offer new fitness programming specifically targeting women facing perimenopause and...

Sean Trahan Joins Citrin Cooperman: New Tax Lead

Citrin Cooperman's Strategic Tax Move If there's one phrase that can spark a debate at a financial water cooler, it's 'transfer pricing.' Today, Citrin Cooperman is throwing its hat further into that ring with the appointment of Sean Trahan as head of their new Transfer Pricing and Value Chain Optimization Practice. This isn't just another reshuffling of office...

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

HTX's Strategic Moves in Pakistan: A Crypto Frontier

Paving the Way: HTX's Journey in Pakistan Rolling into the Pakistan cryptocurrency scene isn't just a 'walk in the park' for HTX—it's more like traversing a new frontier with an open map. This isn’t some hit-and-run operation; HTX is strategizing for a long haul in one of the liveliest digital market arenas in South Asia. Gathering steam with community AMAs and an X...

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...